小馬智行夥三一重工在中國大規模生產自動駕駛貨車
獲豐田汽車入股的中國自動駕駛技術初創公司小馬智行宣布,計劃與三一重工(600031.SH)在中國大規模生產自動駕駛貨車,年產量預計在數年內達到約1萬輛,現時的目標是在今明兩年開始小規模交付,而大規模生產將於2024年開始。
小馬智行稱,貨車使用Nvidia(NVDA.US)Drive Orin晶片,並配備第4級(level 4)自動駕駛技術,允許汽車在高速公路及城市道路上實現完全自動駕駛,不過按照中國現行法規,貨車不可以完全自主駕駛。公司表示,目前在北京及廣州擁有自動駕駛貨車的測試許可,相信日後中國內地或會放寬規定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.